未知生产厂商
Rezafungin is an echinocandin antifungal indicated in patients over 18 years old who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
Rezafungin is an echinocandin antifungal indicated in patients over 18 years old who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
Rezafungin is an echinocandin antifungal drug. It inhibits the 1,3-β-D-glucan synthase enzyme complex present in the cell walls of fungi, responsible for the formation of 1,3-β-D-glucan. Since 1,3-β-D-glucan is an essential component of fungal cell walls, rezafungin disrupts the cell wall of fungal species, including Candida spp., and acts as a concentration-dependent in vitro fungicidal. Mammalian cells do not express β-1-3-glucan synthase; therefore, the action of rezafungin is specific to fungi.
Rezafungin is indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
